S Bank Fund Management Ltd Trims Holdings in AbbVie Inc. $ABBV

S Bank Fund Management Ltd lowered its holdings in AbbVie Inc. (NYSE:ABBV) by 35.0% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 8,252 shares of the company’s stock after selling 4,448 shares during the period. S Bank Fund Management Ltd’s holdings in AbbVie were worth $1,886,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Weil Company Inc. boosted its holdings in AbbVie by 2.3% in the third quarter. Weil Company Inc. now owns 2,026 shares of the company’s stock valued at $469,000 after acquiring an additional 46 shares in the last quarter. Hardin Capital Partners LLC raised its holdings in AbbVie by 1.4% in the 4th quarter. Hardin Capital Partners LLC now owns 3,321 shares of the company’s stock worth $759,000 after purchasing an additional 46 shares in the last quarter. Inlet Private Wealth LLC raised its holdings in AbbVie by 0.3% in the 3rd quarter. Inlet Private Wealth LLC now owns 17,001 shares of the company’s stock worth $3,937,000 after purchasing an additional 47 shares in the last quarter. D.B. Root & Company LLC lifted its position in shares of AbbVie by 4.3% in the 3rd quarter. D.B. Root & Company LLC now owns 1,152 shares of the company’s stock worth $267,000 after purchasing an additional 47 shares during the period. Finally, Redhawk Wealth Advisors Inc. lifted its position in shares of AbbVie by 1.5% in the 4th quarter. Redhawk Wealth Advisors Inc. now owns 3,162 shares of the company’s stock worth $722,000 after purchasing an additional 47 shares during the period. 70.23% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on ABBV. Piper Sandler reduced their price target on shares of AbbVie from $299.00 to $294.00 and set an “overweight” rating on the stock in a research report on Thursday, April 23rd. BMO Capital Markets restated an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. DZ Bank raised AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Thursday, April 30th. Morgan Stanley upped their target price on AbbVie from $270.00 to $278.00 and gave the stock an “overweight” rating in a report on Thursday, April 30th. Finally, Canaccord Genuity Group raised their target price on AbbVie from $262.00 to $265.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and seven have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $252.90.

AbbVie Price Performance

NYSE:ABBV opened at $206.12 on Wednesday. AbbVie Inc. has a one year low of $176.57 and a one year high of $244.81. The company’s 50-day simple moving average is $214.17 and its 200 day simple moving average is $221.34. The firm has a market capitalization of $364.46 billion, a P/E ratio of 101.54, a PEG ratio of 0.72 and a beta of 0.32.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 911.57%. The business had revenue of $15 billion for the quarter, compared to analysts’ expectations of $14.72 billion. During the same quarter in the prior year, the company earned $2.46 earnings per share. The business’s revenue was up 12.4% compared to the same quarter last year. On average, equities research analysts expect that AbbVie Inc. will post 14.3 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 3.4%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio (DPR) is 340.89%.

Insiders Place Their Bets

In other news, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the sale, the senior vice president directly owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. This represents a 66.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Perry C. Siatis sold 22,381 shares of the firm’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares of the company’s stock, valued at $8,771,510. The trade was a 36.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.06% of the stock is currently owned by insiders.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q1 beat and raised guidance spurred a rally: AbbVie reported stronger‑than‑expected Q1 results and lifted 2026 guidance, which pushed the stock higher in early May as investors reassessed growth prospects from Skyrizi, Rinvoq and the pipeline. ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?
• Positive Sentiment: Analyst and retail attention following the quarter: Coverage from Zacks highlights the company as a top‑searched/“trending” stock, reflecting elevated investor interest after the beat — attention that can amplify moves on earnings or guidance news. ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?
• Positive Sentiment: Dividend appeal remains strong: Multiple income‑focused outlets continue to list AbbVie as a high‑yield dividend candidate, supporting demand from dividend investors despite valuation considerations. Want to Collect a High Dividend Every Month? Invest in These 3 Stocks
• Neutral Sentiment: Positive clinical and real‑world data showcased at DDW: AbbVie presented long‑term and real‑world evidence for SKYRIZI (risankizumab) and RINVOQ (upadacitinib) in IBD, which supports the commercial outlook but will take time to materially change revenue trajectory. AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®
• Neutral Sentiment: Industry tech/AI events mention AbbVie involvement: Participation in life‑science AI forums signals digital investment but is unlikely to move near‑term fundamentals. Zifo’s SiEE Boston Summit Charts New Roadmap for ‘Practical AI’ in Life Sciences, Bridging the Gap Between Business Vision and Lab Reality
• Negative Sentiment: Regulatory/manufacturing setback for a wrinkle treatment: The U.S. FDA declined to approve AbbVie’s wrinkle product over manufacturing concerns (reported April 23), a near‑term headwind that can pressure sentiment and highlight execution risk on noncore franchises. US FDA declines to approve AbbVie’s wrinkle treatment due to manufacturing concerns (April 23)

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.